Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 2
2002 2
2003 1
2004 21
2005 59
2006 20
2007 2
2010 1
2011 3
2012 2
2013 6
2014 3
2015 2
2016 2
2017 1
2018 2
2020 5
2021 5
2022 6
2023 2
2024 5
2025 11
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.
Harter P, Trillsch F, Okamoto A, Reuss A, Kim JW, Rubio-Pérez MJ, Vardar MA, Scambia G, Trédan O, Nyvang GB, Colombo N, Bidziński M, Grimm C, Lheureux S, Van Nieuwenhuysen E, Heitz F, Wenham RM, Nishio S, Lim MC, Marquina G, Altundağ Ö, Bergamini A, Sabatier R, Wimberger P, Gold MA, Sehouli J, Park-Simon TW, Kent E, Correa A, Aghajanian C; DUO-O Investigators. Harter P, et al. Among authors: altundag o. Ann Oncol. 2026 Apr;37(4):503-520. doi: 10.1016/j.annonc.2025.11.020. Epub 2025 Dec 9. Ann Oncol. 2026. PMID: 41380962 Free article. Clinical Trial.
Multiple myeloma.
Altundag K, Altundag O, Gundeslioglu O. Altundag K, et al. Among authors: altundag o. N Engl J Med. 2005 Feb 24;352(8):840-1; author reply 840-1. doi: 10.1056/NEJM200502243520823. N Engl J Med. 2005. PMID: 15728824 No abstract available.
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.
Marth C, Moore RG, Bidziński M, Salutari V, Altundağ Ö, Rubio MJ, Levy T, Stillie A, Vulsteke C, Witteler R, Ariyoshi K, Wu X, Frentzas S, Mattar A, Slomovitz BM, Lheureux S, Chen X, Hasegawa K, Magallanes M, Choi CH, Shalkova M, Kaen DL, Cadoo K, Yao L, McKenzie J, Okpara CE, Meng R, Orlowski R, Gilbert L, Makker V. Marth C, et al. Among authors: altundag o. Int J Gynecol Cancer. 2026 Jan;36(1):102795. doi: 10.1016/j.ijgc.2025.102795. Epub 2025 Nov 11. Int J Gynecol Cancer. 2026. PMID: 41494216 Free article. Clinical Trial.
Posttransplant Malignancies in Adult Transplant Patients.
Ramazanoglu MN, Farzaliyeva A, Karakaya E, Oguz A, Akcali Z, Sezgin A, Altundag O, Haberal M. Ramazanoglu MN, et al. Among authors: altundag o. Exp Clin Transplant. 2025 Nov;23(11):730-733. doi: 10.6002/ect.2025.0081. Exp Clin Transplant. 2025. PMID: 41410373 Free article.
146 results